Skip to Main Content

Vadim S. Koshkin


Genitourinary oncologist
Avid traveler and reader, Chicago sports fan and trivia buff

Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are.

In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors.

After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network.

A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time.

  • Education

    University of Chicago Pritzker School of Medicine, 2012

  • Residencies

    University of Michigan, Internal Medicine, 2015

  • Fellowships

    Cleveland Clinic, Hematology/Oncology, 2018

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

Each cancer patient is unique and deserves unique care. This means extra attention to personal needs but also individualized attention to treatment.

Where I see patients (2)

    My reviews


    Overall Experience
    197 Ratings
    About our process
    Oct 05, 2023
    Very knowledgeable open kind and caring
    Sep 09, 2023
    Dr Koshkin is wonderful.
    Jul 28, 2023
    Vadim Koshkin is the best!
    Jul 16, 2023
    As always the Dr. And his Fellow were courteous and professional.
    Jul 07, 2023
    Great job
    Jul 02, 2023
    Dr Koshkin is first class in every way!
    Jun 30, 2023
    Absolute confidence in Dr. Koshkin's medical care and concern for patient's well being.
    May 25, 2023
    I don't know what the outcome was of my visit. I need to no what the Good and the bad please.
    Apr 08, 2023
    Very good job
    Apr 05, 2023
    Dr Koshkin is Excellent!!
    Jan 30, 2023
    Dr Koshkin has always been and continues to be a fantastic physician for me. He treated me successfully for my urethral cancer which included 6 months of chemotherapy. He deserves the highest marks possible.
    Jan 05, 2023
    I have had the very best of attention- from Dr koshkin
    Dec 23, 2022
    Great job
    Oct 12, 2022
    Great job
    Sep 21, 2022
    Dr Koshkin is terrific!
    Aug 23, 2022
    Stays right on top
    Aug 12, 2022
    Very good doctor
    Jul 15, 2022
    I have recommended ucsf
    May 29, 2022
    Dr. Koshkin always makes me feel part of the decision for my treatment. His concern is real and I always feel like he cares.
    May 27, 2022
    May 20, 2022
    Dr Koshkin is Excellent! Great listener
    Apr 17, 2022
    I couldn't have asked for a better doctor.
    Mar 16, 2022
    Excellent care
    Decorative Caduceus

    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer ...

    The time from randomization to first documentation of disease progression per RECIST v1.1 by BICR, or to death due to any cause.


    Decorative Caduceus

    Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...

    If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. Per Invest...


    Decorative Caduceus

    Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...

    The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...


    Decorative Caduceus

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HE...

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1


    Decorative Caduceus

    HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

    The proportion of participants who have a best overall response (BOR) based on complete response (CR) or partial response (PR). The BOR for each participant is the best response (radiographically documented and measurable disease ...


    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.
    This provider is employed by a medical group affiliated with UCSF.